Literature DB >> 18176637

Does glycoprotein IIB/IIIA resistance exist?

J J J Smit1, A W J van 't Hof.   

Abstract

Year:  2007        PMID： 18176637      PMCID： PMC2082084          DOI： 10.1007/bf03086016

Source DB:  PubMed          Journal:  Neth Heart J        ISSN： 1568-5888            Impact factor:   2.380


× No keyword cloud information.
  16 in total

1.  Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.

Authors:  Samer S Kabbani; Atul Aggarwal; Edward F Terrien; Peter M DiBattiste; Burton E Sobel; David J Schneider
Journal:  Am J Cardiol       Date:  2002-03-01       Impact factor: 2.778

2.  Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.

Authors:  David J Schneider; Howard C Herrmann; Nasser Lakkis; Frank Aguirre; Ying Wan; Atul Aggarwal; Samer S Kabbani; Peter M DiBattiste
Journal:  Am J Cardiol       Date:  2002-12-15       Impact factor: 2.778

Review 3.  Determinants of the interindividual variability in response to antiplatelet drugs.

Authors:  B Rocca; C Patrono
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

4.  Platelet function predicts myocardial damage in patients with acute myocardial infarction.

Authors:  Martin Frossard; Ingrid Fuchs; Judith M Leitner; Kety Hsieh; Marianne Vlcek; Heidrun Losert; Hans Domanovits; Wolfgang Schreiber; Anton N Laggner; Bernd Jilma
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

5.  Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.

Authors:  C Michael Gibson; Lisa K Jennings; Sabina A Murphy; David P Lorenz; Robert P Giugliano; Robert A Harrington; Shila Cholera; Rajini Krishnan; Robert M Califf; Eugene Braunwald
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

6.  Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Authors:  Paul A Gurbel; Kevin P Bliden; Joseph DiChiara; Justin Newcomer; Willy Weng; Nagaraj K Neerchal; Tania Gesheff; Srivasavi K Chaganti; Amena Etherington; Udaya S Tantry
Journal:  Circulation       Date:  2007-06-11       Impact factor: 29.690

7.  Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST-elevation acute myocardial Infarction treated by primary percutaneous coronary intervention.

Authors:  Armando Pérez de Prado; Felipe Fernández-Vázquez; J Carlos Cuellas; Norberto Alonso-Orcajo; Raúl Carbonell; Cristina Pascual; Cristina Olalla; Alejandro Diego; Antonio de Miguel; Ramón G Calabozo
Journal:  Am J Cardiol       Date:  2006-01-18       Impact factor: 2.778

8.  Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design.

Authors:  Arnoud W J van 't Hof; Christian Hamm; Saman Rasoul; Soneil Guptha; John F Paolini; Jurriën M Ten Berg
Journal:  EuroIntervention       Date:  2007-11       Impact factor: 6.534

9.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

10.  Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Authors:  Nicolette M S K J Ernst; Harry Suryapranata; Kor Miedema; Robbert J Slingerland; Jan Paul Ottervanger; Jan C A Hoorntje; A T Marcel Gosselink; Jan-Henk E Dambrink; Menko-Jan de Boer; Felix Zijlstra; Arnoud W J van 't Hof
Journal:  J Am Coll Cardiol       Date:  2004-09-15       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.